Celltrion Pharm said on the 19th that Godex, a treatment for hepatic diseases, recorded 7.4 billion won in out-of-hospital prescriptions last month. Based on Ubist data, its market share is 30.4%.
Godex is prescribed for patients with damaged hepatocytes and elevated transaminase levels. Launched in Oct. 2015, it has been co-marketed with Chong Kun Dang pharmaceutical. It has maintained a high share in Korea's out-of-hospital prescription market for more than 10 years.
Celltrion Pharm recently held the 9th symposium on metabolic dysfunction-associated fatty liver disease in Jeju Island. Inha University College of Medicine Professor Lee Jin-woo, Chung-Ang University College of Medicine Professor Kim Hyeong-jung, and Hanyang University College of Medicine Professor Jeon Dae-won attended and discussed fatty liver disease.
A Celltrion Pharm official said, "We will carry out academic activities that help in treatment settings," adding, "We will enhance the product's value."